Comparing Second-Line NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma.

A clinical trial, NCT06783140, is being conducted to compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX. The trial involves two arms: one with NABPLAGEM (Nab-paclitaxel+Cisplatin+Gemcitabine) and the other with Nab-paclitaxel+gemcitabine. The study aims to assess outcomes such as overall response rate, overall survival time, progression-free survival, duration of response, CA19-9 response, and number of adverse events. The trial is not yet recruiting and is expected to be completed by March 3, 2031. [Extracted from the article]